Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry.
Oddone F, Roberti G, Giammaria S, Posarelli C, Ghirelli G, Mastropasqua L, Agnifili L, Micelli Ferrari T, Pace V, Nucci P, Sacchi M, Monsellato G, Altafini R, Scuderi G, Perdicchi A, Uva M, Carnevale C, Covello G, Maglionico MN, Fea A, Figus M. Oddone F, et al. Among authors: uva m. Eye (Lond). 2024 Jan;38(1):103-111. doi: 10.1038/s41433-023-02642-5. Epub 2023 Jul 6. Eye (Lond). 2024. PMID: 37414935 Free PMC article.
Italian Candidates for the XEN Implant: An Overview from the Glaucoma Treatment Registry (XEN-GTR).
Posarelli C, Figus M, Roberti G, Giammaria S, Ghirelli G, Quercioli P, Micelli Ferrari T, Pace V, Mastropasqua L, Agnifili L, Sacchi M, Scuderi G, Perdicchi A, Altafini R, Uva M, D'Andrea D, Covello G, Maglionico MN, Fea AM, Carnevale C, Oddone F. Posarelli C, et al. Among authors: uva m. J Clin Med. 2022 Sep 9;11(18):5320. doi: 10.3390/jcm11185320. J Clin Med. 2022. PMID: 36142967 Free PMC article.
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis.
Lazzaro C, van Steen C, Ghirelli G, Sacchi M, Sisto D, Uva M, Varano L, Angelillo L. Lazzaro C, et al. Among authors: uva m. Expert Rev Pharmacoecon Outcomes Res. 2023 Feb;23(2):251-265. doi: 10.1080/14737167.2023.2161515. Epub 2023 Jan 9. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 36576091 Free article.
The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results.
Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, Katsanos A, Longo A, Uva MG, Oddone F, Torri V, Weinreb RN. Quaranta L, et al. J Glaucoma. 2018 Oct;27(10):856-863. doi: 10.1097/IJG.0000000000001038. J Glaucoma. 2018. PMID: 30095601 Clinical Trial.
Long-term efficacy of latanoprost in primary congenital glaucoma.
Uva MG, Avitabile T, Reibaldi M, Bucolo C, Drago F, Quaranta L, Lionetti E, Longo A. Uva MG, et al. Eye (Lond). 2014 Jan;28(1):53-7. doi: 10.1038/eye.2013.232. Epub 2013 Oct 25. Eye (Lond). 2014. PMID: 24158022 Free PMC article.
An evaluation of the rate of nonresponders to latanoprost therapy.
Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, Carassa R, Mastropasqua L, Quaranta L, Marchini G, Ratiglia R, Orzalesi N. Rossetti L, et al. Among authors: uva m. J Glaucoma. 2006 Jun;15(3):238-43. doi: 10.1097/01.ijg.0000212214.18018.41. J Glaucoma. 2006. PMID: 16778647 Clinical Trial.
167 results